An expert panel of India's drug regulator on Friday sought additional data from drugmaker Dr.Reddy's Laboratories on its Sputnik V COVID-19 vaccine trial, in its second such request after an initial evaluation in February.
The committee asked the company to submit a comparative analysis of late-stage immunogenicity data from both its Indian studies and an ongoing Russian study, as well as data on serious adverse events and positive cases reported till date.
Dr. Reddy's has been conducting small clinical trials with Sputnik V in India under a deal with Russia's wealth fund. Several Indian companies have signed deals to produce and supply over half a billion doses of the vaccine.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
From FLiRT To FLuQE: What To Know About The Latest Covid Variants Covid Still Kills 1,700 A Week Around World: WHO Universal Coronavirus Vaccine? New Jab Targets Even Unknown Threats Parents Gave Names Of Interns, Doctors To CBI In Kolkata Horror: Sources How Extreme Weather Is Leading To Rise In Child Marriages In Pakistan 3 Days After Big Order On Deposits With SBI And PNB, Karnataka Hits Pause "Far From Over" But Joe Biden Has High Hopes For Gaza Ceasefire Indian Student In UK Develops Revolutionary Carbon-Extracting Biomaterial Video: Woman Tries To Jump Off Mumbai's Atal Setu, Saved By Driver, Cops Track Latest News Live on NDTV.com and get news updates from India and around the world.